Menlo Ventures marked its 50th anniversary by announcing $3 billion across two AI funds aimed at seed‑to‑growth startups. The raise expands the firm’s bets in infrastructure, healthcare and enterprise AI.

Blocking an age‑linked enzyme regenerated hyaline cartilage in mice and produced early repair signals in human knee tissue, researchers report.

San Diego’s cAMPfield closed a $180M Series A to advance prifemilast, a once‑daily oral PDE4B inhibitor, into global trials for IBD.

A tiny peptide called BRP cut meals in mice and minipigs and drove fat‑specific weight loss; human testing is not yet underway.

Nobel-winning AlphaFold lead John Jumper is leaving Google DeepMind to join Anthropic, shifting high‑profile AI talent toward San Francisco’s labs.

Cepheid opened a 180,000‑square‑foot Building 5 in Lodi on May 28, 2026, completing a multi‑building manufacturing campus and boosting local diagnostic production.

Midjourney unveiled an AI‑powered full‑body ultrasonic scanner that it says can image a person in about 60 seconds. The company plans a Union Square spa rollout while experts call for independent validation.

San José says its AI Upskilling Program has trained about 1,000 city workers who are building custom AI assistants to speed 311, permitting and emergency readiness.

A Parkfield study using machine learning found short slow‑slip events that boost low‑frequency quakes, prompting scientists to rethink how California's hazard models account for transient stress.

A proposed class‑action alleges Anthropic misled customers about token allowances on its $100 and $200 Claude Max plans and seeks refunds and class certification.

Microsoft CEO Satya Nadella warned that a handful of dominant AI systems could “hollow out entire industries,” urging firms to build private learning loops to protect jobs and IP.

Nvidia plans to sell at least $20 billion of bonds in a seven‑part offering to refinance debt and fund AI investments.

UCSF researchers describe an implanted adaptive DBS system that times stimulation to walking and reduced falls in a small Parkinson's feasibility trial.